Robert H Shoemaker

Summary

Affiliation: National Cancer Institute
Country: USA

Publications

  1. ncbi The NCI60 human tumour cell line anticancer drug screen
    Robert H Shoemaker
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    Nat Rev Cancer 6:813-23. 2006
  2. pmc Transcriptomic response to differentiation induction
    G W Patton
    Screening Technologies Branch, Developmental Therapeutics Program, NCI Frederick, Frederick, MD 21702, USA
    BMC Bioinformatics 7:81. 2006
  3. ncbi Application of high-throughput, molecular-targeted screening to anticancer drug discovery
    Robert H Shoemaker
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute Frederick, Maryland 21702 1201, USA
    Curr Top Med Chem 2:229-46. 2002
  4. pmc Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    Annamaria Rapisarda
    SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1867-77. 2009
  5. pmc Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
    Andrew G Jobson
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4255, USA
    J Pharmacol Exp Ther 331:816-26. 2009
  6. ncbi Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1
    Eun Jung Park
    Science Applications International Corporation, Frederick, Inc, National Cancer Institute at Frederick, Frederick, Maryland 21702 1201, USA
    Cell Cycle 5:1847-53. 2006
  7. pmc Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy
    George T Lountos
    Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    J Struct Biol 176:292-301. 2011
  8. ncbi Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221
    Mark Creighton-Gutteridge
    Screening Technologies Branch, Developmental Therapeutics Program, SAIC Frederick, Inc, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    Clin Cancer Res 13:1010-8. 2007
  9. pmc Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy
    David T Vistica
    Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    J Pediatr Hematol Oncol 31:561-70. 2009
  10. pmc P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA
    Jianfei Zhao
    Laboratory of Metabolism, National Cancer Institute, Bethesda, Maryland 20892, USA
    Mol Pharmacol 82:814-23. 2012

Detail Information

Publications54

  1. ncbi The NCI60 human tumour cell line anticancer drug screen
    Robert H Shoemaker
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    Nat Rev Cancer 6:813-23. 2006
    ..Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy...
  2. pmc Transcriptomic response to differentiation induction
    G W Patton
    Screening Technologies Branch, Developmental Therapeutics Program, NCI Frederick, Frederick, MD 21702, USA
    BMC Bioinformatics 7:81. 2006
    ..The processing of such data typically leads to lists of differentially-regulated genes. A common terminal data analysis step is to map pathways of potentially interrelated genes...
  3. ncbi Application of high-throughput, molecular-targeted screening to anticancer drug discovery
    Robert H Shoemaker
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute Frederick, Maryland 21702 1201, USA
    Curr Top Med Chem 2:229-46. 2002
    ..In this article we discuss the application of high-throughput screening to anti-cancer drug discovery, with special reference to approaches used at the U.S. National Cancer Institute...
  4. pmc Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    Annamaria Rapisarda
    SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1867-77. 2009
    ..These results strongly suggest that combination of anti-vascular endothelial growth factor antibodies with HIF-1 inhibitors is an attractive therapeutic strategy targeting in the hypoxic tumor microenvironment...
  5. pmc Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
    Andrew G Jobson
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4255, USA
    J Pharmacol Exp Ther 331:816-26. 2009
    ..These data indicate that PV1019 is a potent and selective inhibitor of Chk2 with chemotherapeutic and radiosensitization potential...
  6. ncbi Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1
    Eun Jung Park
    Science Applications International Corporation, Frederick, Inc, National Cancer Institute at Frederick, Frederick, Maryland 21702 1201, USA
    Cell Cycle 5:1847-53. 2006
    ..However, NSC 50352 was devoid of activity in cell-based assays. Our results provide proof-of-principle that the PAS-A domain of HIF-1alpha is a valid target for development of small molecule inhibitors...
  7. pmc Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy
    George T Lountos
    Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    J Struct Biol 176:292-301. 2011
    ..The structures reported here elucidate the binding modes of these inhibitors to Chk2 and provide information that can be exploited for the structure-assisted design of novel chemotherapeutics...
  8. ncbi Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221
    Mark Creighton-Gutteridge
    Screening Technologies Branch, Developmental Therapeutics Program, SAIC Frederick, Inc, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    Clin Cancer Res 13:1010-8. 2007
    ..Here, we report on a novel tricyclic carboxamide inhibitor of HIF-1alpha, NSC 644221...
  9. pmc Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy
    David T Vistica
    Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    J Pediatr Hematol Oncol 31:561-70. 2009
    ....
  10. pmc P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA
    Jianfei Zhao
    Laboratory of Metabolism, National Cancer Institute, Bethesda, Maryland 20892, USA
    Mol Pharmacol 82:814-23. 2012
    ..These experiments suggest that antimony containing arylstibonic acids are promising leads for suppression of DNA binding activities of B-ZIP and B-HLH-ZIP transcription factors...
  11. doi Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts
    Anne Monks
    aSTB Laboratory of Functional Genomics, SAIC Frederick Inc, PO Box B, NCI Frederick, 1032 Boyles Street, Frederick, MD 21702, USA
    Anticancer Drugs 20:682-92. 2009
    ..We have demonstrated a gene signature that is selectively regulated by HDACi when compared with other clinical agents allowing us to distinguish HDACi responses from those related to other mechanisms...
  12. pmc Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1
    Nicole D Fer
    Laboratory of Functional Genomics, SAIC Frederick Inc, NCI Frederick, 1050 Boyles Street, Frederick, MD 21702, USA
    J Exp Clin Cancer Res 29:91. 2010
    ....
  13. doi Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii
    Paul Klausmeyer
    Natural Products Support Group, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland 21702, USA
    J Nat Prod 72:805-12. 2009
    ..This work is the first published study of the bioactive phytochemicals of the family Crossosomataceae...
  14. pmc Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide
    Daniela Trisciuoglio
    Tumor Hypoxia Laboratory, SAIC Frederick, Inc, National Cancer Institute, Frederick, MD 21702, USA
    J Natl Cancer Inst 100:1233-46. 2008
    ..Candidaspongiolide (CAN), a novel polyketide from a marine sponge, is the active component of a mixture that was found to be potently cytotoxic in the National Cancer Institute's 60-cell-line screen...
  15. ncbi Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity
    Dehe Kong
    Science Applications International Corporation Frederick, Inc, Frederick, Maryland, USA
    Cancer Res 65:9047-55. 2005
    ..Our results indicate that it is possible to identify small molecules that inhibit HIF-1 DNA binding to endogenous promoters...
  16. pmc Gene expression profiling of alveolar soft-part sarcoma (ASPS)
    Luke H Stockwin
    Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    BMC Cancer 9:22. 2009
    ..In an attempt to gain insight into the pathobiology of this enigmatic tumor, we performed the first genome-wide gene expression profiling study...
  17. doi 12 Arylstibonic acids that inhibit the DNA binding of five B-ZIP dimers
    Vikas Rishi
    Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Building 37, Room 3128, Bethesda, MD 20892, USA
    J Struct Biol 170:216-25. 2010
    ..These experiments suggest that arylstibonic acids are promising leads for inhibiting the DNA binding of a group of B-ZIP proteins in cells...
  18. ncbi Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
    Annamaria Rapisarda
    Science Applications International Corporation Frederick, Inc, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    Cancer Res 64:6845-8. 2004
    ..These results provide a compelling rationale for testing topotecan in clinical trials to target HIF-1 in cancer patients...
  19. pmc Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines
    Constance J Glover
    Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Biochem Pharmacol 73:331-40. 2007
    ..Our findings thus fortify the appeal of mitochondrial complex I as a possible anticancer molecular target and provide a data mining strategy for selecting candidate inhibitors for further testing...
  20. ncbi Targeting topoisomerase I to inhibit hypoxia inducible factor 1
    Annamaria Rapisarda
    Developmental Therapeutics Program, Science Applications International Corporation, Frederick, Inc National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
    Cell Cycle 3:172-5. 2004
    ..In this article, we discuss how topoisomerase I poisons, which inhibit HIF-1a protein accumulation and transcriptional activity, can be "rationally" used to target HIF-1 for cancer therapy...
  21. doi ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma
    Susan Kenney
    Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    J Pediatr Hematol Oncol 33:360-8. 2011
    ..We anticipate that this ASPS cell line will accelerate investigations into the biology of ASPS including identification of new therapeutic approaches for treatment of this slow growing soft tissue sarcoma...
  22. ncbi Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis
    Dorjbal Dorjsuren
    Laboratory of Antiviral Drug Mechanisms, SAIC Frederick, Frederick, MD, USA
    Antiviral Res 69:9-23. 2006
    ..HTS for KSHV POL8/PF8 inhibitors is feasible and may lead to discovery of novel non-nucleoside KSHV DNA synthesis inhibitors...
  23. doi The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells
    Sarah L Heyerdahl
    Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Eur J Cell Biol 89:564-73. 2010
    ..These studies suggest that arylstibonic acid compounds or other small molecules capable of inhibiting B-ZIP DNA binding could be valuable anticancer agents...
  24. pmc Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma
    Vaibhav Saini
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, Maryland, United States of America
    PLoS ONE 7:e41401. 2012
    ....
  25. pmc Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
    Shizuko Sei
    Laboratory of Human Toxicology and Pharmacology, SAIC Frederick, Inc, NCI Frederick, Frederick, Maryland, USA
    Mol Cancer 8:47. 2009
    ..In this study, we investigated the in vitro combination effects of ReoT3D and chemotherapeutic agents against human non-small cell lung cancer (NSCLC)...
  26. doi Separation and SAR study of HIF-1alpha inhibitory tubulosines from Alangium cf. longiflorum
    Paul Klausmeyer
    Natural Products Support Group, SAIC Frederick Inc, NCI Frederick, Frederick, MD 21702, USA
    Planta Med 74:258-63. 2008
    ..Tubulosine strongly inhibited HIF-1 transcriptional activity, isotubulosine was devoid of activity, and 9-desmethyltubulosine possessed 6-fold less potency than tubulosine...
  27. pmc Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα
    Paul Klausmeyer
    Natural Products Support Group, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD 21702 1201, USA
    Bioorg Med Chem 20:4646-52. 2012
    ..The results of this study should encourage future efforts toward obtaining and screening a larger set of both natural and synthetic analogs of this interesting group of alkaloids...
  28. ncbi Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
    Annamaria Rapisarda
    Developmental Therapeutics Program Tumor Hypoxia Laboratory, Science Applications International Corporation Frederick, Inc and National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
    Cancer Res 62:4316-24. 2002
    ..In addition, our results suggest that altered Topo-I function may be associated with repression of HIF-1-dependent induction of gene expression...
  29. pmc X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket
    George T Lountos
    Basic Science Program, SAIC Frederick, Frederick, MD 21702 1201, USA
    FEBS Lett 585:3245-9. 2011
    ..X-ray crystallography was used to determine the structures of the inhibitors in complex with the catalytic kinase domain of Chk2 to verify their modes of binding...
  30. ncbi Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads
    Annamaria Rapisarda
    SAIC Frederick, Inc, Frederick, MD, USA
    Cell Cycle 8:4040-3. 2009
    ....
  31. doi Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa
    Tamara L Meragelman
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland, USA
    J Nat Prod 72:336-9. 2009
    ..Rugulactone was the more active compound, exhibiting up to 5-fold induction of IkappaB at 25 microg/mL; maximal activity was observed with 10 h exposure of test cells to 1 or 2...
  32. doi Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel
    Christina H Stuelten
    Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Stem Cells 28:649-60. 2010
    ....
  33. ncbi Antifungal flavonoids from Hildegardia barteri
    Tamara L Meragelman
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute Frederick, Frederick, Maryland 21702 1201, USA
    J Nat Prod 68:1790-2. 2005
    ..The pterocarpan 2 was largely responsible for the observed antifungal activity...
  34. ncbi Mining the NCI screening database: explorations of agents involved in cell cycle regulation
    Anders Wallqvist
    NCI Frederick, SAIC Frederick, Developmental Therapeutics Program, Screening Technologies Branch, Laboratory of Computational Technologies, Bldg 1052, Room 238, Frederick, MD 21702, USA
    Prog Cell Cycle Res 5:173-9. 2003
    ..These results are consistent with the proposed inactivity of the CYP1A1-mediated metabolism of benzothiazole and the antitumor activity of the metabolically resistant halogenated forms...
  35. ncbi Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications
    Annamaria Rapisarda
    Developmental Therapeutics Program, Tumor Hypoxia Laboratory, Science Applications Corporation Frederick, Inc, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Cancer Res 64:1475-82. 2004
    ..In addition, our findings dissociate the cytotoxic activity of TPT from the inhibition of the HIF-1 pathway and raise the possibility of novel clinical applications of TPT aimed at targeting HIF-1-dependent responses...
  36. pmc Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor
    George T Lountos
    Macromolecular Crystallography Laboratory, National Cancer Institute at Frederick, P O Box B, Frederick, Maryland 21702 1201, USA
    Protein Sci 18:92-100. 2009
    ..A unique hydrophobic pocket in Chk2, located very close to the bound inhibitor, presents an opportunity for the rational design of compounds with higher binding affinity and greater selectivity...
  37. pmc Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4
    Quan en Yang
    Laboratory of Antiviral Drug Mechanisms, Screening Technologies Branch, Developmental Therapeutics Program, SAIC Frederick, NCI Frederick, Bldg 439, P O Box B, Frederick, MD 21702, USA
    J Virol 79:6122-33. 2005
    ..NSC 13778 may represent a prototype of a new class of HIV-1 entry inhibitors that can break into the gp120-CD4 interface and mask the gp120-binding site on the CD4 molecules, effectively repelling incoming virions...
  38. ncbi Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology
    Anders Wallqvist
    Science Applications International Corporation, Frederick, Maryland 21702, USA
    Mol Cancer Ther 1:311-20. 2002
    ..The details of the 11 verifiable cases and the concordant gene subsets are provided. Discussions about the prospects of using this approach as a data mining tool are included...
  39. doi Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells
    Maura Calvani
    Developmental Therapeutics Program, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    Cancer Res 68:285-91. 2008
    ....
  40. ncbi A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors
    Vikas Rishi
    Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Anal Biochem 340:259-71. 2005
    ..These experiments suggest that the DNA binding of B-ZIP transcription factors is a potential target for clinical intervention...
  41. pmc Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus
    Weimin Zhu
    Laboratory of Antiviral Drug Mechanisms, SAIC Frederick, Frederick, Maryland 21702, USA
    Antimicrob Agents Chemother 49:4965-73. 2005
    ..Taken together, N-MCT is a highly potent and target-specific anti-KSHV agent which inhibits lytic KSHV DNA synthesis through its triphosphate metabolite produced in KSHV-infected cells expressing a virally encoded thymidine kinase...
  42. ncbi Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities
    Alfred A Rabow
    Science Applications International Corporation and Developmental Therapeutics Program, DCTD, National Cancer Institute NIH, Frederick, MD 21702, USA
    J Med Chem 45:818-40. 2002
    ..The advantages of a global analysis of the complete screening data set are discussed...
  43. ncbi Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore
    Tam Luong Nguyen
    Target Structure Based Drug Discovery Group, SAIC Frederick, Inc, NCI Frederick, Frederick, MD 21702, USA
    Bioorg Med Chem 14:6097-105. 2006
    ..The RSK2 NTD model was used to identify two novel RSK2 inhibitors from the National Cancer Institute open chemical repository and to develop a preliminary structure-based pharmacophore model...
  44. ncbi A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay
    Constance J Glover
    Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Anal Biochem 320:157-69. 2003
    ..This robust assay offers potential for high-throughput screening discovery of novel compounds simulating the action of Smac/DIABLO...
  45. ncbi Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo
    Joell J Gills
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA
    Clin Cancer Res 13:5183-94. 2007
    ..Because these drugs cause toxicities that can be associated with inhibition of Akt, an emerging target in cancer, we assessed the potential of HIV protease inhibitors as anticancer agents...
  46. doi Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma
    David T Vistica
    Screening Technologies Branch, Developmental Therapeutics, National Cancer Institute, Frederick, MD 21702, USA
    J Pediatr Hematol Oncol 30:46-52. 2008
    ..These antibodies will be useful for the differential diagnosis of type 1 and type 2 ASPS and also in the detection of the fusion proteins in biochemical and cell biologic investigations...
  47. doi Potential for therapeutic targeting of tumor stem cells
    Vaibhav Saini
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, Maryland, USA
    Cancer Sci 101:16-21. 2010
    ..The increasing understanding of aberrantly expressed molecules and signaling pathways in TSCs may provide the foundation for design of therapeutic strategies for TSC ablation...
  48. ncbi Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans
    Paul Klausmeyer
    Natural Products Support Group, SAIC Frederick, Inc, Bldg 431, FCRDC, Frederick, Maryland 21702 1201, USA
    J Nat Prod 68:1300-2. 2005
    ..Preparative isolation work resulted in the identification of the new compounds tetrathioaspirochlorine (2) and cyclo(D-N-methyl-Leu-L-Trp) (3)...
  49. ncbi Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity
    Andrew G Stephen
    Protein Chemistry Laboratory, SAIC Frederick, Inc, NCI Frederick, 21702, Frederick, MD, USA
    Biochem Biophys Res Commun 296:1228-37. 2002
    ..Molecular modeling predicts that these hydroxyl groups would bind to the amide nitrogen of Gly(35) with other contacts at the carbonyl oxygens of Gly(40) and Lys(33)...
  50. ncbi Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors
    Lars H Jensen
    Department of Pathology, Diagnostic Centre, National University Hospital, Copenhagen, Denmark
    Cancer Res 65:7470-7. 2005
    ....
  51. doi New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues
    Aldo Andreani
    Dipartimento di Scienze Farmaceutiche, Universita di Bologna, Via Belmeloro 6, 40126 Bologna, Italy
    J Med Chem 51:809-16. 2008
    ..A few selected compounds were submitted to additional biological studies concerning effects on the cell cycle, apoptosis, and mitochondria...
  52. ncbi Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data
    Anders Wallqvist
    Science Applications International Corporation, National Cancer Institute at Frederick, National Institutes of Health Frederick, MD 21702, USA
    Bioinformatics 19:2212-24. 2003
    ....
  53. ncbi Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors
    Paul Klausmeyer
    Natural Products Support Group, SAIC Frederick, Inc, NCI Frederick, Maryland, USA
    Planta Med 73:49-52. 2007
    ..9,10-Methylenedioxy-(20S)-camptothecin (4) was found for the first time from a plant...
  54. ncbi Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells
    George L Scheffer
    Department of Pathology, Free University Medical Center, De Boelelaan 1117 1081 HV, Amsterdam, The Netherlands
    Eur J Cancer 38:1535-42. 2002
    ....